EphA2 expression is associated with aggressive features in ovarian carcinoma
EphA2 expression is associated with aggressive features in ovarian carcinoma
复制标题
DOI：
10.1158/1078-0432.ccr-03-0589
复制
发表时间：
2004-08-01
影响因子：
11.5
通讯作者：
Sood, AK
中科院分区：
文献类型：
--
作者：
Thaker, PH;Deavers, M;Sood, AK
目的：EphA2（上皮细胞激酶）是一种跨膜受体酪氨酸激酶，与肿瘤发生有关。目前还没有关于 EphA2 在卵巢癌中的作用的公开数据，这是本研究的重点。 实验设计：通过蛋白质印迹分析评估非转化 (HIO-180) 和卵巢癌（EG、222、SKOV3 和 A2780-PAR）细胞系的 EphA2。还通过免疫组织化学评估了 5 个良性卵巢肿块、10 个低度恶性潜能卵巢肿瘤和 79 个浸润性卵巢癌的 EphA2 表达。所有样品均以盲法进行评分。使用单变量和多变量分析来确定EphA2表达与临床病理变量之间的显着关联。结果：通过蛋白质印迹分析，EG、222和SKOV3细胞系过表达EphA2，而A2780-PAR和HIO-180的EphA2表达低至缺失。所有良性肿瘤的 EphA2 表达均较低或不表达。在检查的浸润性卵巢癌中（患者平均年龄为59.2岁），60个（75.9%）肿瘤过度表达EphA2，其他19个肿瘤EphA2表达阴性或极少。 EphA2 过表达与腹水、淋巴结阳性的可能性、病理亚型和最佳手术细胞减灭术（残留肿瘤）没有关联。
Purpose: EphA2 (epithelial cell kinase) is a transmembrane receptor tyrosine kinase that has been implicated in oncogenesis. There are no published data regarding the role of EphA2 in ovarian carcinoma, which is the focus of the present study.Experimental Design: Nontransformed (HIO-180) and ovarian cancer (EG, 222, SKOV3, and A2780-PAR) cell lines were evaluated for EphA2 by Western blot analysis. Five benign ovarian masses, 10 ovarian tumors of low malignant potential, and 79 invasive ovarian carcinomas were also evaluated for EphA2 expression by immunohistochemistry. All samples were scored in a blinded fashion. Univariate and multivariate analyses were used to determine significant associations between EphA2 expression and clinicopathological variables.Results: By Western blot analysis, EG, 222, and SKOV3 cell lines overexpressed EphA2, whereas A2780-PAR and HIO-180 had low to absent EphA2 expression. All of the benign tumors had low or absent EphA2 expression. Among the invasive ovarian carcinomas examined (mean age of patients was 59.2 Years), 60 (75.9%) tumors overexpressed EphA2 and the other 19 tumors had negative or minimal EphA2 expression. There was no association of EphA2 overexpression with ascites, likelihood of nodal positivity, pathological subtype, and optimum surgical cytoreduction (residual tumor